Corazon (Corsee) Sanders Sells 2,627 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Director Corazon (Corsee) Sanders sold 2,627 shares of the business’s stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $340.90, for a total value of $895,544.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

BeOne Medicines Stock Down 1.6%

ONC opened at $330.18 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.39 and a quick ratio of 2.17. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $170.99 and a 12 month high of $385.22. The stock has a market capitalization of $39.14 billion, a P/E ratio of 647.41 and a beta of 0.45. The business has a 50 day simple moving average of $332.69 and a 200-day simple moving average of $301.18.

Analyst Ratings Changes

Several brokerages have commented on ONC. Morgan Stanley boosted their target price on shares of BeOne Medicines from $350.00 to $383.00 and gave the stock an “overweight” rating in a research report on Monday, October 20th. Truist Financial set a $400.00 target price on shares of BeOne Medicines in a research report on Monday, November 24th. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. Finally, Barclays began coverage on BeOne Medicines in a report on Thursday, September 18th. They issued an “overweight” rating and a $385.00 price target on the stock. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $365.79.

Institutional Trading of BeOne Medicines

Several large investors have recently modified their holdings of the business. Parallel Advisors LLC purchased a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $59,000. Aaron Wealth Advisors LLC purchased a new position in BeOne Medicines during the second quarter worth $200,000. Farther Finance Advisors LLC acquired a new position in shares of BeOne Medicines in the second quarter worth $39,000. Avanza Fonder AB purchased a new stake in shares of BeOne Medicines in the second quarter valued at $199,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of BeOne Medicines during the second quarter valued at $3,491,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.